- **1** Supplementary Material for
- 2

3 Monitoring SARS-CoV-2 in wastewater during New York City's second wave of COVID-

4 19: Sewershed-level trends and relationships to publicly available clinical testing data

- 5 Catherine Hoar,^a Francoise Chauvin,^b Alexander Clare,^b Hope McGibbon,^b Esmeraldo Castro,^b
- 6 Samantha Patinella,^b Dimitrios Katehis,^b John J. Dennehy,^{c,d} Monica Trujillo,^e Davida S.
- 7 Smyth, ^{f,g} Andrea I. Silverman^a*
- 8
- ^aDepartment of Civil and Urban Engineering, New York University Tandon School of
- 10 Engineering Brooklyn, NY, USA
- 11 ^bNew York City Department of Environmental Protection, New York, NY, USA
- 12 ^cBiology Department, Queens College, The City University of New York, Queens, NY USA
- 13 ^dBiology Doctoral Program, The Graduate Center, The City University of New York, New York,
- 14 NY, USA
- 15 ^eDepartment of Biology, Queensborough Community College, The City University of New
- 16 York, Bayside, NY, USA
- ^fDepartment of Natural Sciences and Mathematics, Eugene Lang College of Liberal Arts at The
- 18 New School, New York, NY, USA
- 19 ^gpresent affiliation: Department of Life Sciences, Texas A&M University San Antonio, San
- 20 Antonio, Texas, USA
- 21
- 22 *corresponding author: Andrea Silverman, andrea.silverman@nyu.edu
- 23

24 Table of Contents

25	Table S.1. New York City's 14 wastewater resource recovery facilities (WRRFs)	S3
26	Sample Processing and RNA Extraction Methodology	S4
27	RT-qPCR Assays	S 6
28	SARS-CoV-2 N1 Assay	S 6
29 30	Table S.2. MIQE checklist: Essential and desirable information for the SARS-CoV-2 RT-qPCR assay ⁷	N1 target S8

31 32	Figure S.1. SARS-CoV-2 viral loads in wastewater from the Wards Island facility calcula using (a) the individual standard curves associated with the RT-qPCR plate on which each	
33	sample was run and (b) the pooled standard curve.	S13
34	BCoV Assay	S13
35	Publicly Available Clinical COVID-19 Data and Hospitalization Data	S15
36 37	Figure S.2. Summary of COVID-19 testing data (molecular tests) for each sewershed in N York City.	New S16
38 39 40	Figure S.3. Summary of 7-day averages of new cases (solid red line) and hospitalizations (dashed black line) normalized by borough population for each New York City borough the study period.	
41	Sewershed-level Spearman's Rank Correlation Coefficients	S18
42 43	Table S.3. Spearman's rank correlation coefficients (ρ) between SARS-CoV-2 wastewate data and clinical COVID-19 case data for each sewershed in New York City.	er S18
44	Time Lag Analysis	S19
45 46 47	Figure S.4. Spearman rank correlation coefficients (ρ) between SARS-CoV-2 viral loads GC/day) and 7-day averages of new COVID-19 cases/day, with a time lag (τ) between 0 21 days for each sewershed in New York City.	
48	Linear Regression Analysis	S21
49 50 51 52	Figure S.5. Linear regression of log ₁₀ -transformed flow-normalized SARS-CoV-2 viral lo in wastewater (N1 GC/day) and log ₁₀ -transformed 7-day averages of new COVID-19 cases/day for the combined data set without the data filtered based on potentially inadequatesting.	
53	Estimation of Minimum Detectable Case Rates	S22
54 55 56	Table S.4. Estimated minimum detectable case rates (new COVID-19 cases/day/100,000) associated with method LOD for quantification of the SARS-CoV-2 N1 gene target in wastewater (4,500 N1 GC/L) for each sewershed.) S23
57 58 59 60 61	Figure S.6. Estimation of new COVID-19 cases/day associated with the method LOD for quantification of the SARS-CoV-2 N1 gene target in wastewater, based on the linear regression of log ₁₀ -transformed SARS-CoV-2 viral loads (N1 GC/day) and log ₁₀ -transfor 7-day averages of new COVID-19 cases/day for the combined data set (modified from Fi 3.a).	med
62	References	S25
63 64		
65		

66	Table S.1. New York	City's 14 wastewater reso	urce recovery fac	cilities (WRRFs)
67				

Wastewater Resource Recovery Facility (WRRF)	Borough(s)	Population Served*	Daily Flow Range (Average) [†] in MGD
Hunts Point	Bronx	755,948	115 - 215 (136)
Wards Island	Bronx and Manhattan	1,201,485	143 - 273 (180)
North River	Manhattan	658,596	81 - 143 (94)
Newtown Creek	Manhattan and Brooklyn	1,156,473	158 - 296 (188)
Red Hook	Brooklyn	224,029	21 - 46 (26)
Owls Head	Brooklyn	906,442	81 - 159 (95)
Coney Island	Brooklyn	682,342	70 - 102 (82)
26th Ward Brooklyn		290,608	44 - 89 (55)
Rockaway	Queens	120,539	18 - 25 (20)
Jamaica Bay	Queens	748,737	74 - 103 (81)
Tallman Island	Queens	449,907	48 - 90 (59)
Bowery Bay	Queens	924,695	82 - 179 (100)
Port Richmond	Staten Island	226,167	23 - 55 (29)
Oakwood Beach Staten Island		258,731	24 - 41 (28)

*Based on inter-census population estimates for 2020 from the New York Metropolitan Transportation Council's 2050 Socioeconomic and Demographic Forecast¹ *Average (Q_{avg}) is based on daily flows from November 8, 2020 to April 11, 2021

73 Sample Processing and RNA Extraction Methodology

74 Influent wastewater samples were analyzed in 40-mL aliquots using polyethylene glycol (PEG) precipitation for virus concentration. To ensure inactivation of viruses before sample 75 76 concentration, samples were first pasteurized at 60 °C in a water bath for a total of 90 min, which 77 allowed 30 min for the sample to reach 60 °C and then 60 min of incubation at that temperature. 78 Pasteurized samples were cooled in a room temperature water bath for 10 min followed by a 10 79 min incubation on ice prior to addition of an attenuated bovine coronavirus (BCoV) from a 80 bovine rota-coronavirus vaccine (Calf-Guard[®]; Zoetis #4002), which was used as a process 81 control. The BCoV control spike was prepared based on a method modified from Feng et al., 82 2021.² One one-dose vial of the Calf-Guard® vaccine was rehydrated with 1 mL TE buffer 83 (Fisher Scientific, BP2473100) and stored in single-use aliquots at -80 °C. On the day of sample 84 analysis, an aliquot of the vaccine was thawed at room temperature and further diluted 1 in 10 using nuclease-free water. 40 µL of the diluted vaccine was added to each 40-mL sample. This 85 86 spike was added after pasteurization and cooling based on preliminary analysis during protocol development that indicated reduced recovery of BCoV when it was added to the sample prior to 87 88 the pasteurization step. On the contrary, we found pasteurization to increase the measured 89 concentration of the N1 target in our samples, as compared to samples analyzed without the 90 initial pasteurization step (data not shown).

91

92 Solids were then removed from samples through centrifugation at 5000 x g for 10 min at 4 °C (Eppendorf Centrifuge 5804 R or Thermo Fisher Scientific Sorvall X4 Pro Centrifuge). Sample 93 94 supernatant was filtered using 0.22 µm cellulose acetate filters (Corning, 431154). It should be 95 noted that due to brief challenges in obtaining some consumables during the fall of 2020 due to supply chain constraints, alternative filters were used for some batches of samples—namely, (1) 96 97 0.45 µm cellulose nitrate filters (Thermo Scientific Nalgene, 130-4045PK) for samples collected 98 on October 4, 6, and 18, 2020 and (2) 0.22 µm polyethersulfone (Millex-GP, SLGP033RS) for 99 samples collected on November 1, 3, 8, and 10, 2020. A preliminary study indicated that filter 100 type and size may impact virus recovery, so if filters must be used, consistency of filter type and 101 size is preferable.

103 The utility of including the filtration step for sample processing and SARS-CoV-2 virus 104 extraction depends on downstream analysis goals. For example, if extracted RNA will be used 105 for sequencing applications, sample filtration can aid in removing bacterial cells and their nucleic 106 acids, thereby helping to enrich for viral RNA. Preliminary work during protocol development 107 indicated no significant difference between SARS-CoV-2 N1 gene copy concentrations in 108 samples analyzed with and without filtration with 0.22 µm cellulose acetate filters (data not 109 shown). Nonetheless, despite similar viral recoveries with and without filtration, we chose to 110 include the filtration step given logistical benefits, including the prevention of clogging of 111 membranes used in spin-column based RNA extraction methods, and ensuring that no solids 112 were carried over after the centrifugation step. Avoiding the transfer of solids could potentially 113 reduce variability caused by the inclusion of viruses associated with solid material, although 114 further analysis is needed to better understand the distribution of the virus in liquid and solid 115 fractions of wastewater samples and the impact of pasteurization on virus partitioning between 116 these two phases.

117

118 To concentrate viruses in solution, filtered samples were added to 4.0 g of PEG (Fisher 119 Scientific, BP233) and 0.9 g of NaCl (Fisher Scientific, BP358) in 50-mL Oak Ridge high-speed 120 polypropylene copolymer centrifuge tubes (Thermo Scientific Nalgene, 3119-0050), shaken by 121 hand until translucent, and held at 4 °C overnight. Note that 50-mL Oak Ridge high-speed 122 polycarbonate centrifuge tubes (Thermo Scientific Nalgene, 3138-0050) were initially used for 123 sample processing; however, these tubes broke after several uses, possibly due to the 124 polycarbonate's limited resistance to chemicals used in the RNA extraction (see below). The next day, samples were centrifuged at 12,000 x g for 120 min at 4 °C (Eppendorf Centrifuge 125 126 5804 R or Thermo Fisher Scientific Sorvall X4 Pro Centrifuge) to pellet the PEG and associated 127 virus particles.

128

RNA was extracted from concentrated PEG pellets using the Qiagen QIAamp Viral RNA Mini
Kit (Qiagen, 52906; ethanol purchased separately, Fisher Scientific, BP2818500) following the
vacuum protocol with a QIAvac 24 Plus (Qiagen, 19413), with the modifications specified here.
First, 1.6x the suggested lysis buffer volume (i.e., 1.7 mL) was added directly to the PEG pellet
in the Oak Ridge polycarbonate tube in which it was centrifuged to ensure recovery of the entire

- pellet. Note that samples processed prior to February 1, 2021 were extracted with 3x the
- 135 suggested lysis buffer volume, originally used in an effort to maximize PEG pellet recovery. A
- 136 subsequent study confirmed no significant difference in recovery using either 1.6x or 3x the
- 137 suggested lysis buffer volume (data not shown). RNA was eluted in 60 µL of kit-supplied AVE
- buffer through a series of two 30 µL-elutions (Eppendorf Centrifuge 5424 R) and stored in
- 139 aliquots at -80 °C until quantification by RT-qPCR.
- 140

141 RT-qPCR Assays

142 SARS-CoV-2 N1 Assay

- 143 A one-step RT-qPCR assay based on the CDC Diagnostic Panel was used to quantify gene
- 144 copies of the N1 region of the SARS-CoV-2 (GenBank accession no. MN908947) nucleocapsid
- 145 (N) gene [72-base amplicon, 28287 (starting position) 28358 (ending position)].^{3–5} Triplicate 20
- 146 μL reactions each contained 5 μL of 4x TaqPath 1-Step RT-qPCR Master Mix (Thermo Fisher
- 147 Scientific, A15299); 1.5 μL of the 2019-nCoV RUO Kit primer/probe mix (Integrated DNA
- 148 Technologies, 10006713) containing 6.7 μM forward primer (5'-
- 149 GACCCCAAAATCAGCGAAAT-3'), 6.7 μM reverse primer (5'-
- 150 TCTGGTTACTGCCAGTTGAATCTG-3'), and 1.7 μM probe (5'-FAM-
- 151 ACCCCGCATTACGTTTGGTGGACC-BHQ-1-3'); 5 μL of template RNA; and 8.5 μL of
- 152 nuclease-free water. Note that initial 2019-nCoV RUO Kits contained probes synthesized with
- 153 Black Hole Quencher 1 (BHQ-1), while later kits contained probes synthesized with
- 154 Zen/IowaBlack quenchers, according to correspondence with Integrated DNA Technologies.
- 155 Thus, RT-qPCR conducted later in the study period used probes with Zen/IowaBlack quenchers.
- 156 Data provided by the CDC for the limit of detection equivalence between probes with the two
- 157 quencher types showed that the lowest detectable concentration at which all replicates were
- 158 positive was the same for the two quencher types when using TaqPath 1-Step RT-qPCR Master
- 159 Mix.⁴
- 160
- 161 Each 96-well RT-qPCR plate included triplicate no template controls (nuclease-free water).
- 162 Synthetic SARS-CoV-2 RNA covering > 99.9% of the viral genome (Twist Bioscience Control
- 163 1, GENBANK ID MT007544.1; Twist Bioscience, 102019) served as both a positive control and

- standard used in a decimal serial dilution for quantification of N1 gene copies. Standard
- 165 concentrations used for quantification ranged from 5×10^5 copies/rxn (equivalent to 1.5×10^8
- 166 copies/L of sample) to the limit of quantification (LOQ), which was 50 copies/rxn (equivalent to
- 167 1.5×10^4 copies/L of sample). The LOQ, determined as described by Forootan et al. 2017,⁶ was
- 168 the concentration for which the coefficient of variation (CV) on concentrations of replicate
- standards calculated using measured Cq values was $\leq 35\%$ (CV = 34% for the LOQ in this
- 170 study). Note that these concentrations are relative to the approximate concentration of synthetic
- 171 RNA control reported by the manufacturer, as described in the main text.
- 172
- 173 Reactions were aliquoted manually into 0.1 mL MicroAmp[™] Fast Optical 96-Well Reaction
- 174 Plates (Thermo Fisher Scientific, 4346907), which were covered with MicroAmp[™] Optical
- 175 Adhesive Films (Thermo Fisher Scientific, 4311971). RT-qPCR analysis for the SARS-CoV-2
- 176 N1 gene was conducted on a StepOnePlus Real-Time PCR System (ThermoFisher, 4376600)
- 177 with the following cycling conditions: hold at 25 °C for 2 min, 50 °C for 15 min, and 95 °C for 2
- 178 min, followed by 45 cycles of 95 °C for 3 sec and 55 °C for 30 sec. The MIQE checklist for
- 179 reporting essential and desirable information⁷ for the N1 assay can be found in Table S.2.
- 180

181 Table S.2. MIQE checklist: Essential and desirable information for the SARS-CoV-2 N1

182 target RT-qPCR assay⁷

ITEM TO CHECK	IMPORTANCE	CHECKLIST
EXPERIMENTAL DESIGN		
Definition of experimental and control groups	Е	Provided in Materials and Methods
Number within each group	E	Provided in Materials and Methods
Assay carried out by core lab or investigator's lab?	D	Assay carried out by NYC DEP lab
Acknowledgement of authors' contributions	D	
SAMPLE		
Description	Е	Provided in Materials and Methods
Volume/mass of sample processed	D	Provided in Materials and Methods
Microdissection or macrodissection	Е	N/A
Processing procedure	Е	Provided in Materials and Methods
If frozen - how and how quickly?	Е	N/A
If fixed - with what, how quickly?	Е	N/A
Sample storage conditions and duration (especially for FFPE samples)	Е	Provided in Materials and Methods
NUCLEIC ACID EXTRACTION	Ľ	rovided in materials and methods
Procedure and/or instrumentation	E	Provided in Materials and Methods /SI
Name of kit and details of any modifications	E	Provided in Materials and Methods /SI
Source of additional reagents used	D	Provided in SI
Details of DNase or RNAse treatment	E	N/A
Contamination assessment (DNA or RNA)	E	Method blanks included
Nucleic acid quantification	E	RNA concentrations not routinely measured
Instrument and method	E	N/A
Purity (A260/A280)	D	N/A
Yield	D	N/A
RNA integrity method/instrument	E	Not determined
RIN/RQI or Cq of 3' and 5' transcripts	E	N/A
Electrophoresis traces	D	N/A
Inhibition testing (Cq dilutions, spike or other)	E	Discussed in Results and Discussion
REVERSE TRANSCRIPTION	-	
Complete reaction conditions	Е	Provided in SI
Amount of RNA and reaction volume	E	Provided in SI
Priming oligonucleotide (if using GSP) and		
concentration	Е	Provided in SI
Reverse transcriptase and concentration	E	Provided in SI
Temperature and time	Е	Provided in SI

Table S.2. MIQE checklist continued

Manufacturer of reagents and catalogue numbers	D	Provided in SI
Cqs with and without RT	D*	Not determined
Storage conditions of cDNA	D	N/A (one-step RT-qPCR)
qPCR TARGET INFORMATION		
If multiplex, efficiency and LOD of each assay.	Ε	N/A
Sequence accession number	Ε	Provided in SI
Location of amplicon	D	Provided in SI
Amplicon length	Ε	Provided in SI
In silico specificity screen (BLAST, etc)	Ε	N/A
Pseudogenes, retropseudogenes or other homologs?	D	N/A
Sequence alignment	D	N/A
Secondary structure analysis of amplicon	D	N/A
Location of each primer by exon or intron (if	_	
applicable)	Е	N/A
What splice variants are targeted?	Ε	N/A
qPCR OLIGONUCLEOTIDES		
Primer sequences	Ε	Provided in SI
RTPrimerDB Identification Number	D	Not provided
Probe sequences	D**	Provided in SI
Location and identity of any modifications	Е	N/A
Manufacturer of oligonucleotides	D	Provided in SI
Purification method	D	Not provided
qPCR PROTOCOL		
Complete reaction conditions	Ε	Provided in SI
Reaction volume and amount of cDNA/DNA	Ε	Provided SI (one-step RT-qPCR)
Primer, (probe), Mg++ and dNTP concentrations	E	Provided in SI (TaqPath [™] 1-Step RT- qPCR Master Mix, CG)
Polymerase identity and concentration	E	Provided in SI (TaqPath [™] 1-Step RT- qPCR Master Mix, CG)
Buffer/kit identity and manufacturer	E	Provided in SI (TaqPath [™] 1-Step RT- qPCR Master Mix, CG)
Exact chemical constitution of the buffer	D	Provided in SI (TaqPath [™] 1-Step RT- qPCR Master Mix, CG)
Additives (SYBR Green I, DMSO, etc.)	Ε	N/A
Manufacturer of plates/tubes and catalog number	D	Provided in SI
Complete thermocycling parameters	Е	Provided in SI
Reaction setup (manual/robotic)	D	Provided in SI
Manufacturer of qPCR instrument	Ε	Provided in SI

Table S.2. MIQE checklist *continued*

qPCR VALIDATION		
Evidence of optimisation (from gradients)	D	Not determined
Specificity (gel, sequence, melt, or digest)	Е	N/A
For SYBR Green I, Cq of the NTC	Е	N/A
Standard curves with slope and y-intercept	Е	Provided in SI
PCR efficiency calculated from slope	Е	Provided in SI
Confidence interval for PCR efficiency or standard		
error	D	Provided in SI
r2 of standard curve	Е	Provided in SI
Linear dynamic range	Е	Provided in SI
Cq variation at lower limit	Е	Provided in SI
Confidence intervals throughout range	D	Not provided
Evidence for limit of detection	Е	Provided in Materials and Methods
If multiplex, efficiency and LOD of each assay.	Е	N/A
DATA ANALYSIS		
qPCR analysis program (source, version)	Е	Provided in SI
Cq method determination	Е	Provided in SI
Outlier identification and disposition	Е	Provided in SI
Results of NTCs	Е	Provided in Materials and Methods
Justification of number and choice of reference genes	Е	N/A
Description of normalisation method	Е	N/A
Number and concordance of biological replicates	D	N/A
Number and stage (RT or qPCR) of technical		
replicates	E	Provided in Materials and Methods
Repeatability (intra-assay variation)	Е	Triplicate RT-qPCR reactions (SD included)
Reproducibility (inter-assay variation, %CV)	D	Not determined
Power analysis	D	Not determined
Statistical methods for result significance	Е	N/A
Software (source, version)	Е	Provided in SI
Cq or raw data submission using RDML	D	Not provided

183

184

186 Cq values were determined based on the automatic Cq threshold assigned by the StepOneTM

187 Software v2.3 (ThermoFisher). The mean and standard deviation of automatic Cq threshold

across all plates were 0.30 and 0.065, respectively. Any RT-qPCR plates assigned an automatic

189 Cq threshold more than two standard deviations above or below the mean automatic Cq

190 threshold were designated as outlier Cq thresholds and reanalyzed with a manual Cq threshold

- set at 0.31, the mean Cq threshold calculated after the outlier Cq thresholds were removed.
- 192


193 An approximate concentration of the synthetic RNA control used for standard curve preparation 194 was specified by the supplier. Concentrations of standards prepared from the first lot of this 195 control purchased by the research team (referred to as the "original" lot) were determined 196 assuming this approximate concentration. Data from nine standard curves generated with the 197 original lot of synthetic RNA control (analyzed on different RT-qPCR plated on different days) 198 were pooled to obtain one reference standard curve for the original lot. RNA target 199 concentrations of subsequent lots of the synthetic RNA control were each different from that of the original lot, as evidenced by different Cq values of each point on the standard curve (data not 200 201 shown). Because absolute quantification (e.g., using ddPCR) of the RNA control was not 202 feasible at the time that sample analysis began, concentrations of subsequent lots of the RNA 203 control were quantified using measured Cq values of the new lot of the RNA control and the 204 pooled reference standard curve for the original lot (i.e., assuming the approximate quantity 205 reported by the manufacturer). Note that quantification of the RNA control through digital PCR 206 is underway, and N1 concentrations reported in the current version of this work may therefore be 207 updated in future versions to reflect the quantified concentration of the RT-qPCR standard.

208


209 The quality assurance and quality control guidelines developed internally for the NYC DEP's 210 SARS-CoV-2 monitoring program established an acceptable range of amplification efficiencies 211 between 70% and 115%. PCR amplification efficiencies for all N1 assay plates ranged between 72% and 109%, with R² values for all standard curves ≥ 0.97 . Of the 37 individual N1 assay 212 213 plates from the study period (samples collected between November 8, 2020 and April 11, 2021), 214 two resulted in efficiencies less than 85% and none resulted in an efficiency over 110%, 215 indicating consistent acceptable performance of the assay over the five-month period of 216 statistical analysis. It should be noted that variations in amplification efficiency--calculated based

217	on the slope of the standard curvemay reflect errors or inconsistencies in preparation of
218	standards rather than changes in actual PCR amplification efficiency of the assay. We considered
219	variation in standard preparation a possibility, given that RT-qPCR plates were prepared by
220	multiple analysts, with new serial dilutions of the standard prepared for each plate. To account
221	for this potential variability and reduce any resulting noise in the data, we elected to apply a
222	pooled standard curve to calculate N1 concentrations of all samples. The pooled standard curve
223	was developed by combining data of standard curves from 56 plates (samples from September 8,
224	2020 to April 11, 2021); standard curves were pooled after the concentration adjustments of each
225	lot of the RNA control described above were performed. The resulting pooled standard curve had
226	a slope = -3.52, PCR efficiency = 92% (with 95% confidence interval of 91% to 94%), y-
227	intercept = 41.01, and R^2 = 0.99. A comparison of N1 concentrations measured for the Wards
228	Island facility using (a) individual and (b) pooled standard curves (Figure S.1) demonstrates how
229	this approach addresses variability due to errors during standard curve preparation without
230	affecting general trends in the data.
231	
232	
233	
234	
235	
236	

a. Individual RT-qPCR Standard Curves



b. Pooled RT-qPCR Standard Curve





238 Figure S.1. SARS-CoV-2 viral loads in wastewater from the Wards Island facility

calculated using (a) the individual standard curves associated with the RT-qPCR plate on

240 which each sample was run and (b) the pooled standard curve.

241 Influent SARS-CoV-2 viral loads were normalized by the sewershed population. Error bars

242 indicate standard deviations from triplicate RT-qPCR reactions as well as standard deviations of

243 duplicate samples, where applicable. The dashed black line represents a LOESS fit (span = 0.4), 244 with the 95% confidence intervals shaded in grey.

- 245
- 246

247 **BCoV** Assay

- 248 A one-step RT-qPCR assay adapted from previously published assays^{2,8,9} targeting the
- transmembrane (M) gene of BCoV was used to assess recovery of the process control (primers
- and probes purchased from Integrated DNA Technologies). Triplicate 20 µL reactions each
- 251 contained 5 μL of TaqPath 1-Step RT-qPCR Master Mix (4x, ThermoFisher), 1.5 μL of the
- 252 primer/probe mix containing 5 μM forward primer (5'- CTGGAAGTTGGTGGAGTT-3'), 5 μM
- 253 reverse primer (5'- ATTATCGGCCTAACATACATC-3'), and 2.5 μM probe (5'-FAM-
- 254 CCTTCATAT/Zen/CTATACACATCAAGTTGTT/3IABkFQ-3'), 5 μL of template RNA, and
- 8.5 μL of nuclease-free water. Each PCR plate included triplicate no template controls (nuclease-
- 256 free water). A custom gBlocks gene fragments oligo (Integrated DNA Technologies) (5'-

258 ACTTGATGTGTATAGATATGAAGGGAAGGATGTATGTTAGGCCGATAATTGAGGAC

259 TACCATACCCTTA-3') served as both the positive control and standard used in a decimal serial

260 dilution for quantification of gene copies. RT-qPCR analysis was conducted on a StepOnePlus

Real-Time PCR System (ThermoFisher) with the following cycling conditions: hold at 25 °C for

262 2 min, 50 °C for 15 min, and 95 °C for 12 min, followed by 45 cycles of 95 °C for 3 sec, 55 °C

263 for 30 sec, and 60 °C for 1 min.

264

261

Relative standard deviations (*RSD*) of both N1 concentrations and BCoV target concentrations for duplicate samples were calculated using equation S1, where SD_{GC} is the standard deviation and AVG_{GC} is the average gene copy concentration from duplicate samples, each with triplicate RT-qPCR reactions.

$$269 \quad RSD = \frac{SD_{GC}}{AVG_{GC}} \times 100\%$$


Equation S1

270 In general, the relative standard deviation for concentrations of the BCoV target were not 271 consistent with those of the N1 target in a given sample, indicating that quantified recovery of 272 the BCoV control inoculated into samples before virus concentrations and extraction may not 273 accurately reflect recovery of SARS-CoV-2. Limitations of using proxy control viruses have been discussed elsewhere.¹⁰ Calculated recoveries based on the known concentration of the 274 275 BCoV control spike were therefore not used to adjust N1 gene copy concentrations. However, if 276 the BCoV control was not recovered in any sample for which N1 was also not detected, that 277 sample was flagged for failed processing and was excluded from trend analysis or, when 278 possible, full analysis starting from pasteurization was repeated. If the BCoV control was 279 detected in a sample, any non-detect wells from the N1 target assay for that sample were 280 assigned a concentration of zero, which was used in calculating the reported average 281 concentration from triplicate wells.

283 Publicly Available Clinical COVID-19 Data and Hospitalization Data

284

285 Figure S.2. summarizes the COVID-19 clinical testing data set obtained from publicly available 286 data provided by the NYC Department of Health and Mental Hygiene (DOHMH). Figure S.2. 287 includes, for each sewershed, the 7-day average of (1) the percentage of positive clinical 288 COVID-19 tests, (2) new cases/day, and (3) tests/day for the past 7 days. Note that the 289 percentage of positive clinical COVID-19 tests calculated as described in the main text, using the 290 "last7days-by-modzcta.csv" data set, differs from the percent positivity calculated by NYC 291 DOHMH in publicly available data sets such as "percentpositive-by-modzcta.csv", which 292 accounts for duplication related to an individual being tested more than once during a 7-day 293 period.¹¹ The percentage of positive clinical COVID-19 tests we calculated for this analysis was 294 used only for an estimate of adequate testing (i.e., for filtering the combined data set to remove 295 data for dates with percentages of positive molecular tests (7-day average) that exceeded 10%) 296 and not for direct comparison to the wastewater data. Data from March 15, 2021 - March 21, 297 2021 were omitted due to technical issues related to data transmission. COVID-19 case data used 298 in correlation and linear regression analyses were not normalized by population. 299 300 Figure S.3 summarizes borough-level hospitalizations from the NYC DOHMH's publicly available "hosp-by-day.csv" file.¹¹ Borough populations were based on MODZCTA-level 301 302 population estimates from the NYC DOHMH's NYC Coronavirus Disease 2019 (COVID-19) Data.¹¹ Detailed information for the publicly available datasets was retrieved from: 303 304 https://github.com/nychealth/coronavirus-data.




306

Figure S.2. Summary of COVID-19 testing data (molecular tests) for each sewershed in
New York City.

S16

Figure S.2. *caption continued from previous page*. For each sewershed, top panels: 7-day average of the percentage of positive clinical COVID-19 tests for the past 7 days. Bottom panels: 7-day average of new cases/day for the past 7 days (left y-axes) and 7-day average of tests/day for the past 7 days (right y-axes), both normalized by the estimated sewershed population. Note that the left and right y-axes in the bottom panels have different scales. Data used for correlation analysis described in the main manuscript text is shown (November 8, 2020 to May 2, 2021).

- 316
- 317



- 318
- 319 Figure S.3. Summary of 7-day averages of new cases (solid red line) and hospitalizations
- 320 (dashed black line) normalized by borough population for each New York City borough for321 the study period.
- 322 Data is organized by the last date in the 7-day period for which average was calculated. Note that
- 323 the left and right y-axes have different scales.

324 Sewershed-level Spearman's Rank Correlation Coefficients

325 Table S.3. Spearman's rank correlation coefficients (ρ) between SARS-CoV-2 wastewater

326 data and clinical COVID-19 case data for each sewershed in New York City.

327 Column 1: Coefficients for correlations between SARS-CoV-2 *viral loads* in wastewater (N1

328 GC/day) and 7-day averages of new COVID-19 cases/day, as described in the main manuscript

329 text. Column 2: Coefficients for correlations between SARS-CoV-2 concentrations in

- 330 wastewater (N1 GC/L) and 7-day averages of new COVID-19 cases/day normalized by
- 331 sewershed populations. The alternative analysis presented in column 2 was used to assess any
- differences in correlation strengths due to flow normalization of wastewater data (i.e., to
- 333 calculate viral loads, column 1). Significance levels: *p < 0.05, **p < 0.01, ***p < 0.001, 334 ****p < 0.0001.
- 335


	Column 1	Column 2		
Data used for correlation	SARS-CoV-2 Viral Loads (N1 GC/day)	SARS-CoV-2 Concentrations (N1 GC/L)		
analysis	New COVID-19 cases/day	New COVID-19 cases/day/100,000		
Hunts Point	0.60***	0.54***		
Wards Island	0.81****	0.80****		
North River	0.52**	0.49**		
Newtown Creek	0.55***	0.52**		
Red Hook	0.55***	0.51**		
Owls Head	0.59***	0.56***		
Coney Island	0.38*	0.39*		
26th Ward	0.64****	0.59***		
Rockaway	0.68****	0.66****		
Jamaica Bay	0.49**	0.54***		
Tallman Island	0.55***	0.52**		
Bowery Bay	0.46**	0.38*		
Port Richmond	0.48**	0.38*		
Oakwood Beach	0.40*	0.41*		

336 Time Lag Analysis

337

338 To assess whether SARS-CoV-2 viral loads (N1 GC/day) measured in wastewater were a leading

- indicator for 7-day averages of new COVID-19 cases/day, Spearman's rank correlation
- 340 coefficients between the two for lag times ranging from 0-21 days for each sewershed were
- 341 assessed (Figure S.4). The time lag represents the number of days the clinical data was shifted
- back in time in relation to the date of wastewater sample collection. The optimal lag time (i.e.,
- 343 the number of days the clinical data lagged behind the wastewater data to result in the strongest
- 344 correlation) varied for each sewershed, with minimal improvement in correlations associated
- 345 with a lag time (Figure S.4). No significant correlations were found between the optimal lag time
- and the average testing rate for the study period for any sewersheds.




348 Figure S.4. Spearman rank correlation coefficients (*ρ*) between SARS-CoV-2 viral loads




- and 21 days for each sewershed in New York City.
- 351 The time lag represents the number of days the clinical data was shifted back in time.
- 352 Correlations that were not statistically significant (p > 0.05) have been omitted.

353 Linear Regression Analysis

354 Assessment of linear regressions presented in Figures 2 and 3 in the main manuscript confirmed 355 that (1) the slope between log₁₀-transformed viral loads (N1 GC/day) and log₁₀-transformed new 356 cases/day was significantly different from zero (F test; the assumption of significantly non-zero 357 slopes held true for both the combined data set and all facilities individually, with the exception 358 of Port Richmond), (2) a significant linear relationship was present (Pearson, p < 0.05; the 359 assumption of significant linear relationships held true for both the combined data set and all 360 facilities individually, with the exception of Port Richmond), (3) there were no clear patterns 361 observed in residuals (though exceptions were made for some outliers which we elected to retain 362 in the data), and (4) residuals were normally distributed based on the Shapiro-Wilks test ($\alpha =$ 363 0.05) considered alongside visual inspection of histograms and quantile-quantile plots. Note that 364 linear regressions were performed using log₁₀-transformed data; linear regressions with raw, 365 untransformed data generally resulted in fits with lower R² values and more frequent cases of 366 residuals that were not normally distributed than did regressions with the log_{10} -transformed 367 transformed data set.





```
370 loads in wastewater (N1 GC/day) and log<sub>10</sub>-transformed 7-day averages of new COVID-19
```

```
371 cases/day for the combined data set without the data filtered based on potentially
```

- 372 inadequate testing.
- 373 This figure is presented for comparison to Figure 3 in the main text, which excludes data
- 374 collected on dates with over 10% positive testing results. The linear regression (solid line) and
- associated 95% confidence intervals (dashed lines) are shown along with the goodness of fit R^2
- 376 value. The Spearman's rank correlation coefficient (ρ) between N1 GC/day and new COVID-19
- 377 cases/day is shown at the top left, with the significance level indicated (****p < 0.0001).

378 Estimation of Minimum Detectable Case Rates

379

Table S.4 summarizes the estimated minimum number of cases per day per 100,000 people in

- ach sewershed required to detect N1 in influent wastewater based on the method LOD.
- 382 Estimates were calculated using both individual linear regressions for each WRRF and the linear
- 383 regression for the combined data set using Equations 3 and 4 in the main text. To assess whether
- the estimates calculated based on SARS-CoV-2 viral loads differed from those obtained using
- 385 SARS-CoV-2 concentrations without flow normalization, estimates were also determined using
- 386 linear regressions of N1 concentrations in wastewater (N1 GC/L) and new COVID-19
- 387 cases/day/100,000. The same range of estimates (2 8 cases/day/100,000) was obtained from
- 388 linear regressions using both pairs of data sets.

390 Table S.4. Estimated minimum detectable case rates (new COVID-19 cases/day/100,000) associated with method LOD for quantification of the SARS-CoV-2 N1 gene target in 391

392 wastewater (4,500 N1 GC/L) for each sewershed.

393 The Oakwood Beach and Port Richmond sewersheds were excluded from analysis, as described in the main text, but 394 information for all sewersheds is included here for completeness.

	New COVID-19 cases/day/100,000 associated with method LOD					
	Based on linear regressions of N1 GC/day and new COVID-19 cases/day			Based on linear regressions of N1 GC/L and new COVID-19 cases/day/100,000 [†]		
Sewershed (WRRF)	Sewershed-			Sewershed-	Regression from	
	specific regressions	(a) all data	(b) rise	(c) decline	specific regressions	combined data set
Hunts Point	5	2	2	3	5	5
Wards Island	2	2	2	2	2	1
North River	8	2	2	2	8	1
Newtown Creek	4	2	2	2	5	1
Red Hook	3	2	2	3	4]
Owls Head	3	2	2	2	3]
Coney Island	6	2	2	2	6]
26th Ward	5	3	4	4	5]
Rockaway	8	4	4	5	8	
Jamaica Bay	2	2	2	2	3]
Tallman Island	2	3	3	3	3]
Bowery Bay	8	2	2	2	NA [‡]]
Port Richmond	NA [‡]	3	3	3	NA [‡]]
Oakwood Beach	20	3	3	3	21]

395


*Linear regressions were determined using (a) "all data": all data from the combined data set, (b) "rise": data from 396 the combined data set associated with the rise in case rates (data prior to January 2021), or (c) "decline": data from 397 the combined data set associated with the decline in case rates (data after January 2021). Note that the combined 398 data set does not include data from Port Richmond or Oakwood Beach and has been filtered to exclude data

399 associated with over 10% positive tests.


400 [†]Estimates from these regressions are not flow-dependent; therefore, only one estimate is determined from the 401 combined data set.

402 [‡]Slope of associated linear regression not significantly non-zero; linear regression rejected and case rate estimate not

403 calculated 404 Figure S.6 illustrates graphically the approach used to estimate the equivalent number of 405 COVID-19 cases/day/100,000 people associated with the SARS-CoV-2 quantification method 406 LOD using linear regression for the combined data set. First, the method LOD was converted to 407 a SARS-CoV-2 viral loading rate in wastewater (in units of N1 GC/day) for each sewershed 408 using Equation 3 in the main text. The average daily flow rate for each WRRF (Q_{ava}) ranged from 21 MGD (Rockaway WRRF) to 188 MGD (Newtown Creek WRRF), resulting in a range 409 of LOD-equivalent viral loads between 3.5×10^{11} to 3.2×10^{12} N1 GC/day across the facilities. 410 411 The estimated minimum new COVID-19 cases/day required to detect SARS-CoV-2 in 412 wastewater influent were determined by inputting this viral load into Equation 4 (main text) with 413 the slope (m) and y-intercept (b) values from the linear regression (Figure S.6). The resulting 414 COVID-19 cases/day (ranging from 4 to 17 new cases/day) were then normalized by the 415 respective sewershed populations to obtain estimates ranging from 2 to 4 new COVID-19 416 cases/day/100,000. The same approach was applied for each sewershed-level linear regression. 417



418



420 quantification of the SARS-CoV-2 N1 gene target in wastewater, based on the linear

421 regression of log₁₀-transformed SARS-CoV-2 viral loads (N1 GC/day) and log₁₀-

- 422 transformed 7-day averages of new COVID-19 cases/day for the combined data set
- 423 (modified from Figure 3.a).

424 The method LOD (in units of N1 GC/day) for the range of average flow rates (21 MGD at

425 Rockaway WRRF - 188 MGD at Newtown Creek WRRF) for all facilities is indicated in the

426 shaded grey region along the x-axis. The associated minimum detectable new COVID-19

427 cases/day is indicated in the shaded grey region along the y-axis. Estimates from this approach

428 were normalized by sewershed populations.

429 References

- 430 1 2050 SED Forecasts, https://www.nymtc.org/DATA-AND-MODELING/SED-
- 431 Forecasts/2050-Forecasts, (accessed 12 April 2021).
- 432 2 S. Feng, A. Roguet, J. S. McClary-Gutierrez, R. J. Newton, N. Kloczko, J. G. Meiman and S.
- L. McLellan, Evaluation of Sampling, Analysis, and Normalization Methods for SARS-CoV2 Concentrations in Wastewater to Assess COVID-19 Burdens in Wisconsin Communities,
- 435 *ACS EST Water*, 2021, **1**, 1955–1965.
- 3 X. Lu, L. Wang, S. K. Sakthivel, B. Whitaker, J. Murray, S. Kamili, B. Lynch, L. Malapati, S.
 A. Burke, J. Harcourt, A. Tamin, N. J. Thornburg, J. M. Villanueva and S. Lindstrom, US
 CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory
 Syndrome Coronavirus 2, *Emerg Infect Dis*, 2020, 26, 1654–1665.
- 440 4 Centers for Disease Control and Prevention, Division of Viral Diseases, CDC 2019-Novel
 441 Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel: Instructions for Use, CDC442 006-00019, Revision 06, 2020.
- 5 Division of Viral Diseases, National Center for Immunization and Respiratory Diseases,
 Centers for Disease Control and Prevention, Atlanta, GA, USA, 2019-Novel Coronavirus
 (2019-nCoV) Real-time rRT-PCR Panel Primers and Probes, 2020.
- 446 6 A. Forootan, R. Sjöback, J. Björkman, B. Sjögreen, L. Linz and M. Kubista, Methods to
 447 determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR),
 448 *Biomol Detect Quantif*, 2017, 12, 1–6.
- 7 S. A. Bustin, V. Benes, J. A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T.
 Nolan, M. W. Pfaffl, G. L. Shipley, J. Vandesompele and C. T. Wittwer, The MIQE
 Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR
 Experiments, *Clin Chem*, 2009, 55, 611–622.
- 8 N. Decaro, G. Elia, M. Campolo, C. Desario, V. Mari, A. Radogna, M. L. Colaianni, F.
 Cirone, M. Tempesta and C. Buonavoglia, Detection of bovine coronavirus using a TaqManbased real-time RT-PCR assay, *J Virol Methods*, 2008, **151**, 167–171.
- 9 S. Loeb, One-Step RT-ddPCR for Detection of SARS-CoV-2, Bovine Coronavirus, and
 PMMoV RNA in RNA Derived from Wastewater or Primary Settled Solids, *protocols.io*,
 2020, DOI:10.17504/protocols.io.bi6vkhe6.
- 459 10 R. S. Kantor, K. L. Nelson, H. D. Greenwald and L. C. Kennedy, Challenges in Measuring the
 460 Recovery of SARS-CoV-2 from Wastewater, *Environ. Sci. Technol.*, 2021, 55, 3514–3519.
- 461 11 nychealth/coronavirus-data, https://github.com/nychealth/coronavirus-data, (accessed 20 May
- **462** 2021).